<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591639</url>
  </required_header>
  <id_info>
    <org_study_id>AC20006</org_study_id>
    <nct_id>NCT04591639</nct_id>
  </id_info>
  <brief_title>The DAPA-MEMRI Trial</brief_title>
  <acronym>DAPA-MEMRI</acronym>
  <official_title>An Observational Cross-sectional Study and a Double-blind Placebo Controlled Randomised Controlled Trial to Assess the Effect of Dapagliflozin on Myocardial Calcium-handling in Patients With Heart Failure- The DAPA-MEMRI Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus is among the top 10 causes of death worldwide with an increasing incidence.&#xD;
      Patients with diabetes are at risk of developing heart failure which is characterised by&#xD;
      significant changes in the heart muscle including scarring and thickening. Contraction of the&#xD;
      heart involves movement of calcium across the heart muscle and disruption of this process is&#xD;
      an early change seen in heart failure. Recently, a drug therapy (SGLT2 inhibitor therapy) in&#xD;
      patients with diabetes was shown to benefit patients with heart failure but the mechanisms of&#xD;
      benefit are unknown.&#xD;
&#xD;
      Our hypothesis is that calcium handling is altered in patients with either type 2 diabetes&#xD;
      mellitus (T2DM) or heart failure and that SGLT2 inhibitors can improve this in heart failure&#xD;
      irrespective of the presence of T2DM.&#xD;
&#xD;
      Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its&#xD;
      structure and function by using a new contrast 'dye' containing manganese that has shown&#xD;
      advantages over traditional contrast. We plan to further test this new dye as it has the&#xD;
      potential to track and quantify improvements in heart function over time and detect changes&#xD;
      in calcium handling in the heart muscle, making it an ideal measure to identify the&#xD;
      mechanisms of benefit from SGLT2 inhibitor therapy.&#xD;
&#xD;
      The study population will comprise patients with heart failure with and without type 2&#xD;
      diabetes, patients with type 2 diabetes without heart failure and healthy volunteers.&#xD;
      Baseline comparisons will be made between the four groups before progressing to the&#xD;
      randomised controlled trial with heart failure patients only. Patients will have a clinical&#xD;
      assessment and blood tests, electrocardiogram, echocardiogram and MRI of the heart at each&#xD;
      visit.&#xD;
&#xD;
      If successful, this study will give us significant insights into mechanisms of action of&#xD;
      SGLT2 inhibitors in heart failure and will enable us to tailor specific treatments in heart&#xD;
      failure patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to investigate the myocardial calcium handling in patients with heart&#xD;
      failure with or without type 2 diabetes mellitus and if Dapagliflozin (study drug) improves&#xD;
      the myocardial calcium handling in patients with heart failure and diabetes mellitus.&#xD;
&#xD;
      We propose to conduct this study in two parts.&#xD;
&#xD;
        1. OBSERVATIONAL CROSS-SECTIONAL STUDY&#xD;
&#xD;
           An observational cross-sectional study will be undertaken to compare myocardial calcium&#xD;
           in patients with diabetes mellitus and normal left ventricular ejection fraction (n=20),&#xD;
           patients with heart failure in the absence of diabetes mellitus (n=60), and patients&#xD;
           with both diabetes mellitus and heart failure (n=60). They will be compared with healthy&#xD;
           volunteers (n=20).&#xD;
&#xD;
           There will be an initial meeting, where informed consent will be documented and a&#xD;
           medical assessment including blood tests will be undertaken as well as an echocardiogram&#xD;
           will be performed. Healthy volunteers will only undergo Manganese enhanced cardiac MRI&#xD;
           scan. The other cohorts will undergo a gadolinium enhanced cardiac MRI scan on their&#xD;
           first visit. On a subsequent visit, they will undergo 1 cardiac Manganese enhanced&#xD;
           Manganese MRI scan (MEMRI) which lasts 45-60 minutes. Participants will be monitored&#xD;
           with blood pressure and ECG monitoring throughout the MEMRI scan. Patients will be&#xD;
           offered an anti-sickness medication if required following the MEMRI scan.&#xD;
&#xD;
        2. RANDOMISED CONTROLLED TRIAL&#xD;
&#xD;
      We will undertake a randomised double-blind placebo controlled trial of patients with heart&#xD;
      failure with (n=60) and without (n=60) type 2 diabetes mellitus. These participants would&#xD;
      have been recruited as part of the observational study as described above from out-patient&#xD;
      clinics at the Edinburgh Heart Centre. If all eligibility criteria are met, patients will be&#xD;
      randomised to receive treatment with either Dapagliflozin 10 mg, or matched placebo, once&#xD;
      daily for 6 months at a ratio of 1:1. Detailed clinical assessment including history and&#xD;
      examination, blood sampling, electrocardiogram, echocardiogram and cardiac MRI will be&#xD;
      collected at baseline, 1 and 6 months.&#xD;
&#xD;
      There will also be a 3 month safety visit after randomisation to record any adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">August 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The observational component of the study will have 4 cohort of participants (patients with type 2 diabetes without heart failure, patients with heart failure with or without diabetes and healthy volunteers) The randomised controlled trial component of the study will have 2 groups of patients - heart failure with or without type 2 diabetes</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>As above</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in myocardial T1 values with manganese enhanced cardiac MRI</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction measured in percentage on cardiac MRI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass measured in grams on cardiac MRI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac biomarkers like N-terminal pro B-type natriuretic peptide in nanogram per litre</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of diabetes control including glucose in millimoles per litre</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical measures such as heart rate in beats per minute</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracellular volume in percentage as per cardiac MRI measurements</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global longitudinal strain in percentage as calculated on cardiac MRI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical measures such as body weight in Kilograms</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical measures such as blood pressure in millimetres of mercury</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac biomarkers like high sensitivity cardiac troponin I in nanogram per litre</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of glucose control like glycated haemoglobin (HbA1c) in millimoles per mole</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diabetic Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Patients with heart failure without type 2 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with heart failure with type 2 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 milligrams [Farxiga]</intervention_name>
    <description>Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.</description>
    <arm_group_label>Patients with heart failure with type 2 diabetes</arm_group_label>
    <arm_group_label>Patients with heart failure without type 2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.</description>
    <arm_group_label>Patients with heart failure with type 2 diabetes</arm_group_label>
    <arm_group_label>Patients with heart failure without type 2 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with heart failure (with or without type 2 diabetes mellitus)&#xD;
&#xD;
          -  Aged over 18 years&#xD;
&#xD;
          -  Diagnosis of symptomatic reduced ejection fraction heart failure for at least 2 months&#xD;
&#xD;
          -  Left ventricular ejection fraction ≤40%&#xD;
&#xD;
          -  Elevated N-terminal pro B-type natriuretic peptide (&gt;125 pg/mL)&#xD;
&#xD;
          -  Clinical diagnosis of type 2 diabetes mellitus for 50% of patient population - on&#xD;
             stable therapy for at least 12 months or more.&#xD;
&#xD;
        Patients with Type 2 Diabetes Mellitus and no heart failure&#xD;
&#xD;
          -  Aged over 18 years&#xD;
&#xD;
          -  Clinical diagnosis of type 2 diabetes mellitus (diagnosed by either HbA1c of&#xD;
             48mmol/mol (6.5%) or greater or fasting plasma glucose level of 7mmol/L or greater at&#xD;
             the time of diagnosis)&#xD;
&#xD;
             - on stable therapy for at least 12 months or more.&#xD;
&#xD;
          -  Normal left ventricular systolic ejection fraction&#xD;
&#xD;
        Healthy Volunteers&#xD;
&#xD;
          -  Aged over 18 years&#xD;
&#xD;
          -  Normal left ventricular ejection fraction and glycaemia&#xD;
&#xD;
          -  No clinically significant co-morbid conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with heart failure (with or without type 2 diabetes mellitus)&#xD;
&#xD;
          -  Receiving an SGLT2 inhibitor within 8 weeks of enrolment&#xD;
&#xD;
          -  Previous intolerance of, or contraindication to, an SGLT2 inhibitor&#xD;
&#xD;
          -  Standard magnetic resonance imaging safety exclusions&#xD;
&#xD;
          -  Severe renal impairment (eGFR &lt;30millilitre/min. 1.73m2)&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Symptomatic hypotension or systolic blood pressure &lt;95 mmHg&#xD;
&#xD;
          -  Recent (within 12 weeks) hospitalisation for heart failure, acute cardiovascular event&#xD;
             (such as myocardial infarction or stroke) or coronary re-vascularisation.&#xD;
&#xD;
          -  2nd or 3rd degree atrioventricular block Atrial fibrillation or flutter with poor&#xD;
             ventricular rate control (&gt;100 /min)&#xD;
&#xD;
          -  Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive&#xD;
             pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary&#xD;
             valvular disease&#xD;
&#xD;
          -  New York Heart Association grade IV heart failure&#xD;
&#xD;
          -  Obstructive liver function testing abnormalities&#xD;
&#xD;
          -  Concomitant digoxin, diltiazem or verapamil therapy.&#xD;
&#xD;
        Patients with type 2 diabetes mellitus and no heart failure&#xD;
&#xD;
          -  Other major clinically significant co-morbid conditions&#xD;
&#xD;
          -  History of ischaemic heart disease or present history suggestive of probable&#xD;
             clinically significant underlying ischaemic heart disease&#xD;
&#xD;
          -  Standard magnetic resonance imaging safety exclusions&#xD;
&#xD;
          -  Moderate or severe renal impairment (eGFR &lt;45 mL/min. 1.73m2)&#xD;
&#xD;
          -  Receiving a SGLT2 inhibitor at any time&#xD;
&#xD;
          -  Symptomatic hypotension or systolic blood pressure &lt;95 mmHg&#xD;
&#xD;
          -  Abnormal electrocardiogram&#xD;
&#xD;
          -  Clinically significant abnormalities of clinical haematology or biochemistry&#xD;
             measurements.&#xD;
&#xD;
        Healthy Volunteers&#xD;
&#xD;
          -  Major or clinically significant cardiovascular disease&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Receiving an SGLT2 inhibitor at any time&#xD;
&#xD;
          -  Standard magnetic resonance imaging safety exclusions&#xD;
&#xD;
          -  Moderate or severe renal impairment (eGFR &lt;45 mL/min. 1.73m2)&#xD;
&#xD;
          -  Symptomatic hypotension or systolic blood pressure &lt;95 mmHg&#xD;
&#xD;
          -  Abnormal electrocardiogram&#xD;
&#xD;
          -  Clinically significant abnormalities of clinical haematology or biochemistry&#xD;
             measurements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shruti Joshi, MBBS, MRCP</last_name>
    <phone>0131 650 1000</phone>
    <email>sjoshi@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Newby, PhD, BM, DM, MRCP, DSc, FRSE</last_name>
    <phone>0131 650 1000</phone>
    <email>d.e.newby@ed.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shruti Joshi, MBBS, MRCP</last_name>
      <phone>0131 650 1000</phone>
      <email>sjoshi@ed.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Sodium glucose Co-transporter 2 inhibitor therapy</keyword>
  <keyword>Manganese enhanced cardiac magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

